Annual Report

Overview

The report describes the Phase III CBD insomnia trial reaching 190 dosed patients toward approximately 210 required for interim analysis, and records an exclusive Australian licensing agreement with Sandoz. It reports consolidated revenue of $1,237,762 and a loss after tax of $4,416,623 for 2025. The company also raised $2.5 million through a November placement to accelerate commercial manufacturing and clinical-trial activities.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2025
Period: Ends 31 December 2025
Publication date: 27 February 2026
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services